MIRA Pharmaceuticals, Inc. Common Stock Net Assets
MIRA Pharmaceuticals, Inc. Common Stock net assets. Based on the latest financial reports, MIRA Pharmaceuticals, Inc. Common Stock (MIRA) has net assets worth $8.16 Million USD as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($8.20 Million) and total liabilities ($40.82K). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore net asset momentum of MIRA Pharmaceuticals, Inc. Common Stock to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $8.16 Million |
| % of Total Assets | 99.5% |
| Annual Growth Rate | N/A |
| 5-Year Change | 359.53% |
| 10-Year Change | N/A |
| Growth Volatility | 219.3 |
Net Assets of MIRA Pharmaceuticals, Inc. Common Stock (2020–2025)
Net assets of MIRA Pharmaceuticals, Inc. Common Stock from 2020 to 2025. This chart illustrates how MIRA Pharmaceuticals, Inc. Common Stock's net assets have evolved over time, based on quarterly financial data. See MIRA equity financing ratio to measure how much of total assets are equity-financed.
Annual Net Assets for MIRA Pharmaceuticals, Inc. Common Stock (2020–2025)
The table below shows the annual net assets of MIRA Pharmaceuticals, Inc. Common Stock from 2020 to 2025. For live market cap and overall valuation, see MIRA Pharmaceuticals, Inc. Common Stock market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $10.39 Million | +372.40% |
| 2024-12-31 | $2.20 Million | -49.71% |
| 2023-12-31 | $4.37 Million | +833.67% |
| 2022-12-31 | $-596.23K | -126.37% |
| 2021-12-31 | $2.26 Million | +3425.87% |
| 2020-12-31 | $-67.99K | -- |
Equity Component Analysis
This analysis shows how different components contribute to MIRA Pharmaceuticals, Inc. Common Stock's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 3951221300.0% over the analyzed period, potentially due to dividend distributions or operating losses.
MIRA Pharmaceuticals, Inc. Common Stock Net Assets Breakdown (December 2025)
MIRA Pharmaceuticals, Inc. Common Stock net assets breakdown by equity component as of December 2025.
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $4.19K | 0.04% |
| Other Components | $49.97 Million | 480.85% |
| Total Equity | $10.39 Million | 100.00% |
MIRA Pharmaceuticals, Inc. Common Stock Competitors by Market Cap
The table below lists competitors of MIRA Pharmaceuticals, Inc. Common Stock ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Maat Pharma SA
PA:MAAT
|
$22.58 Million |
|
First Au Ltd
AU:FAU
|
$22.58 Million |
|
Daebo Magnetic Co.Ltd
KQ:290670
|
$22.58 Million |
|
First Graphene Ltd
AU:FGR
|
$22.59 Million |
|
Petratherm Ltd
AU:PTR
|
$22.57 Million |
|
Jasa Kita Bhd
KLSE:8648
|
$22.57 Million |
|
Bonava AB (publ)
ST:BONAV-A
|
$22.56 Million |
|
Rifa Ind
KO:000760
|
$22.56 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in MIRA Pharmaceuticals, Inc. Common Stock's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 2,199,750 to 10,391,537, a change of 8,191,787 (372.4%).
- Net loss of 10,442,485 reduced equity.
- New share issuances of 7,006,982 increased equity.
- Other factors increased equity by 11,627,290.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-10.44 Million | -100.49% |
| Share Issuances | $7.01 Million | +67.43% |
| Other Changes | $11.63 Million | +111.89% |
| Total Change | $- | 372.40% |
Book Value vs Market Value Analysis
This analysis compares MIRA Pharmaceuticals, Inc. Common Stock's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.22x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2020-12-31 | $0.00 | $0.54 | x |
| 2021-12-31 | $0.15 | $0.54 | x |
| 2022-12-31 | $-0.04 | $0.54 | x |
| 2023-12-31 | $0.24 | $0.54 | x |
| 2024-12-31 | $0.14 | $0.54 | x |
| 2025-12-31 | $0.44 | $0.54 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently MIRA Pharmaceuticals, Inc. Common Stock utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -100.49%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.07x
- Recent ROE (-100.49%) is above the historical average (-137.94%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2020 | 0.00% | 0.00% | 0.00x | 0.00x | $-61.19K |
| 2021 | -96.25% | 0.00% | 0.00x | 1.48x | $-2.40 Million |
| 2022 | 0.00% | 0.00% | 0.00x | 0.00x | $-7.00 Million |
| 2023 | -273.92% | 0.00% | 0.00x | 1.13x | $-12.42 Million |
| 2024 | -356.98% | 0.00% | 0.00x | 1.33x | $-8.07 Million |
| 2025 | -100.49% | 0.00% | 0.00x | 1.07x | $-11.48 Million |
Industry Comparison
This section compares MIRA Pharmaceuticals, Inc. Common Stock's net assets metrics with peer companies in the Drug Manufacturers - General industry.
Industry Context
- Industry: Drug Manufacturers - General
- Average net assets among peers: $16,474,638,100
- Average return on equity (ROE) among peers: 35.21%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| MIRA Pharmaceuticals, Inc. Common Stock (MIRA) | $8.16 Million | 0.00% | 0.01x | $22.57 Million |
| AbbVie Inc (ABBV) | $3.36 Billion | 127.17% | 39.18x | $356.49 Billion |
| Amgen Inc (AMGN) | $4.31 Billion | 26.39% | 0.25x | $198.99 Billion |
| Amarin Corporation PLC (AMRN) | $459.28 Million | -8.45% | 0.46x | $254.36 Million |
| AstraZeneca PLC (AZN) | $16.64 Billion | 18.03% | 2.81x | $282.04 Billion |
| AstraZeneca PLC (AZN) | $16.64 Billion | 18.03% | 2.81x | $246.25 Billion |
| Biogen Inc (BIIB) | $13.03 Billion | 34.00% | 0.94x | $32.27 Billion |
| Bristol-Myers Squibb Company (BMY) | $6.02 Billion | 32.59% | 0.79x | $128.73 Billion |
| Gilead Sciences Inc (GILD) | $22.65 Billion | 23.78% | 1.72x | $182.40 Billion |
| GlaxoSmithKline PLC ADR (GSK) | $7.57 Billion | 61.92% | 2.59x | $111.15 Billion |
| Johnson & Johnson (JNJ) | $74.05 Billion | 18.68% | 0.79x | $574.95 Billion |
About MIRA Pharmaceuticals, Inc. Common Stock
MIRA Pharmaceuticals, Inc. operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a next-generation oral NMDA receptor modulator, that has completed a Phase 1 clinical trial. It also offers oral pharmaceutical mar… Read more